These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 34174842)

  • 1. Effect of Oral carnosine supplementation on urinary TGF-β in diabetic nephropathy: a randomized controlled trial.
    Siriwattanasit N; Satirapoj B; Supasyndh O
    BMC Nephrol; 2021 Jun; 22(1):236. PubMed ID: 34174842
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of 12 weeks carnosine supplementation on renal functional integrity and oxidative stress in pediatric patients with diabetic nephropathy: a randomized placebo-controlled trial.
    Elbarbary NS; Ismail EAR; El-Naggar AR; Hamouda MH; El-Hamamsy M
    Pediatr Diabetes; 2018 May; 19(3):470-477. PubMed ID: 28744992
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elevation of urinary betaig-h3, transforming growth factor-beta-induced protein in patients with type 2 diabetes and nephropathy.
    Ha SW; Kim HJ; Bae JS; Jeong GH; Chung SC; Kim JG; Park SH; Kim YL; Kam S; Kim IS; Kim BW
    Diabetes Res Clin Pract; 2004 Aug; 65(2):167-73. PubMed ID: 15223229
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of dual blockade of the renin-angiotensin system on urinary protein and transforming growth factor-beta excretion in 2 groups of patients with IgA and diabetic nephropathy.
    Song JH; Lee SW; Suh JH; Kim ES; Hong SB; Kim KA; Kim MJ
    Clin Nephrol; 2003 Nov; 60(5):318-26. PubMed ID: 14640237
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of statins in patients with diabetic nephropathy: a meta-analysis of randomized controlled trials.
    Shen X; Zhang Z; Zhang X; Zhao J; Zhou X; Xu Q; Shang H; Dong J; Liao L
    Lipids Health Dis; 2016 Oct; 15(1):179. PubMed ID: 27733168
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial.
    Bakris GL; Agarwal R; Chan JC; Cooper ME; Gansevoort RT; Haller H; Remuzzi G; Rossing P; Schmieder RE; Nowack C; Kolkhof P; Joseph A; Pieper A; Kimmeskamp-Kirschbaum N; Ruilope LM;
    JAMA; 2015 Sep; 314(9):884-94. PubMed ID: 26325557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Urinary transforming growth factor-beta excretion in patients with hypertension, type 2 diabetes, and elevated albumin excretion rate: effects of angiotensin receptor blockade and sodium restriction.
    Houlihan CA; Akdeniz A; Tsalamandris C; Cooper ME; Jerums G; Gilbert RE
    Diabetes Care; 2002 Jun; 25(6):1072-7. PubMed ID: 12032117
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Urinary measurement of transforming growth factor-beta and type IV collagen as new markers of renal injury: application in diabetic nephropathy.
    Ellis D; Forrest KY; Erbey J; Orchard TJ
    Clin Chem; 1998 May; 44(5):950-6. PubMed ID: 9590367
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral supplementation of turmeric attenuates proteinuria, transforming growth factor-β and interleukin-8 levels in patients with overt type 2 diabetic nephropathy: a randomized, double-blind and placebo-controlled study.
    Khajehdehi P; Pakfetrat M; Javidnia K; Azad F; Malekmakan L; Nasab MH; Dehghanzadeh G
    Scand J Urol Nephrol; 2011 Nov; 45(5):365-70. PubMed ID: 21627399
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased excretion of urinary transforming growth factor beta 1 in patients with diabetic nephropathy.
    Sato H; Iwano M; Akai Y; Kurioka H; Kubo A; Yamaguchi T; Hirata E; Kanauchi M; Dohi K
    Am J Nephrol; 1998; 18(6):490-4. PubMed ID: 9845822
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Cytokines in noninvasive diagnostics of diabetic nephropathy progression].
    Senatorski G; Paczek L; Kropiewnicka E; Bartłomiejczyk I
    Pol Merkur Lekarski; 2002 Nov; 13 Suppl 1():28-32. PubMed ID: 12621778
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Urine TGF-beta1 concentration in patients with type II diabetes mellitus--prognostic values].
    Paczek L; Kropiewnicka HE; Senatorski G; Bartłomiejczyk I
    Pol Arch Med Wewn; 2002 Aug; 108(2):745-52. PubMed ID: 12476894
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of low-dose dual blockade of renin-angiotensin system on urinary TGF-beta in type 2 diabetic patients with advanced kidney disease.
    Song JH; Cha SH; Lee HJ; Lee SW; Park GH; Lee SW; Kim MJ
    Nephrol Dial Transplant; 2006 Mar; 21(3):683-9. PubMed ID: 16330466
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Increased urinary excretion of transforming growth factor beta and interleukin-6 in patients with diabetic nephropathy].
    Królak R; Paczek L; Rogala H; Bartłomiejczyk I; Gradowska L; Korczak D; Gaciong Z
    Pol Arch Med Wewn; 1996 Dec; 96(6):545-51. PubMed ID: 9139274
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Resveratrol reduces albuminuria in diabetic nephropathy: A randomized double-blind placebo-controlled clinical trial.
    Sattarinezhad A; Roozbeh J; Shirazi Yeganeh B; Omrani GR; Shams M
    Diabetes Metab; 2019 Jan; 45(1):53-59. PubMed ID: 29983230
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High urinary sulfate concentration is associated with reduced risk of renal disease progression in type 2 diabetes.
    van den Born JC; Frenay AR; Bakker SJ; Pasch A; Hillebrands JL; Lambers Heerspink HJ; van Goor H
    Nitric Oxide; 2016 May; 55-56():18-24. PubMed ID: 26952289
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased renal GLUT1 abundance and urinary TGF-beta 1 in streptozotocin-induced diabetic rats: implications for the development of nephropathy complicating diabetes.
    D'Agord Schaan B; Lacchini S; Bertoluci MC; Irigoyen MC; Machado UF; Schmid H
    Horm Metab Res; 2001 Nov; 33(11):664-9. PubMed ID: 11733869
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blockade of TSP1-dependent TGF-β activity reduces renal injury and proteinuria in a murine model of diabetic nephropathy.
    Lu A; Miao M; Schoeb TR; Agarwal A; Murphy-Ullrich JE
    Am J Pathol; 2011 Jun; 178(6):2573-86. PubMed ID: 21641382
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of sulodexide on urinary biomarkers of kidney injury in normoalbuminuric type 2 diabetes: a randomized controlled trial.
    Satirapoj B; Kaewput W; Supasyndh O; Ruangkanchanasetr P
    J Diabetes Res; 2015; 2015():172038. PubMed ID: 25918727
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rationale, design, and baseline characteristics of ARTS-DN: a randomized study to assess the safety and efficacy of finerenone in patients with type 2 diabetes mellitus and a clinical diagnosis of diabetic nephropathy.
    Ruilope LM; Agarwal R; Chan JC; Cooper ME; Gansevoort RT; Haller H; Remuzzi G; Rossing P; Schmieder RE; Nowack C; Ferreira AC; Pieper A; Kimmeskamp-Kirschbaum N; Bakris GL
    Am J Nephrol; 2014; 40(6):572-81. PubMed ID: 25591469
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.